Matching trials
1,853 results
- BATIndependent statistical analysis of the BAT phase 3 trial evaluating prolonged azithromycin treatment in patients with bronchiectasis, including trial design, endpoints, methodology, and interpretation.
- BAY 0 9867 Cipro Pediatric Use Study (QUIP): Complete Statistical AnalysisIndependent statistical analysis of BAY 0 9867 Cipro Pediatric Use Study (QUIP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00761462).
- BE HEARD IIIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa: primary endpoint results, effect estimate with confidence interval, sample-size…
- BE READYIndependent statistical analysis of A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic…
- BE VIVIDIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis: primary…
- BEACONAn independent statistical analysis of the randomized phase 3 BEACON trial evaluating QVA149 against concurrent QAB149 plus NVA237 in patients with chronic obstructive pulmonary disease, including its mixed-model FEV1 endpoint and study…
- BEACONIndependent statistical analysis of Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease…
- BEATccIndependent statistical analysis of the randomized phase 3 BEATcc trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab in metastatic carcinoma of the cervix, including trial design, endpoints, planned survival analysis,…
- BEe-HIVeIndependent statistical analysis of B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BEGIN™Independent statistical analysis of Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BEGIN™Independent statistical analysis of Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- BEGIN™Independent statistical analysis of Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BEGIN™Independent statistical analysis of Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01079234).
- BEGSIndependent statistical analysis of Benralizumab for Eosinophilic Gastritis (BEGS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03473977).
- Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01351766).
- BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115: Complete Statistical AnalysisIndependent statistical analysis of BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115: primary endpoint…
- BELLE-2Independent statistical analysis of the BELLE-2 phase 3 trial of BKM120 plus fulvestrant versus placebo plus fulvestrant in postmenopausal patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer refractory to…
- BELLE-4Independent statistical analysis of A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation: primary endpoint results,…
- Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients: Complete Statistical AnalysisIndependent statistical analysis of Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BENEGENE-2Independent statistical analysis of A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B: primary endpoint results,…
- BESTFITIndependent statistical analysis of BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01903265).
- BETonMACEComplete statistical analysis of the BETonMACE phase 3 trial of apabetalone versus placebo in high-risk patients with type 2 diabetes and coronary artery disease, including time-to-event methodology, hazard ratios, confidence intervals, p-values,…
- BeyondComplete statistical analysis of the Beyond phase 3 trial of interferon beta-1b in relapsing-remitting multiple sclerosis, including trial design, registered endpoints, safety analyses, confidence intervals, and statistical interpretation.
- BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size…
- BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1): Complete Statistical AnalysisIndependent statistical analysis of BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1): primary endpoint results, effect estimate with confidence interval,…
- BIG 1-98A detailed statistical analysis of BIG 1-98, a randomized phase 3 trial of letrozole and tamoxifen citrate in postmenopausal women with breast cancer, focusing on disease-free survival and its time-to-event analysis.
- BILCAPIndependent statistical analysis of the BILCAP phase 3 trial evaluating capecitabine or observation after surgery in patients with biliary tract cancer, including trial design, the 2-year survival endpoint, statistical methodology, and interpretation.
- Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face: Complete Statistical AnalysisIndependent statistical analysis of Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent: Complete Statistical AnalysisIndependent statistical analysis of BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bladder Scan of Residual Urine With New Catheter: Complete Statistical AnalysisIndependent statistical analysis of Bladder Scan of Residual Urine With New Catheter: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01048541).
- BLAZE-2Complete statistical analysis of BLAZE-2, a randomized phase 3 trial evaluating bamlanivimab for prevention of COVID-19 in nursing home residents and staff, including trial design, endpoints, logistic regression methodology, reported results, and…
- BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults: Complete Statistical AnalysisIndependent statistical analysis of BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study): Complete Statistical AnalysisIndependent statistical analysis of BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.: Complete Statistical AnalysisIndependent statistical analysis of BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen: Complete Statistical AnalysisIndependent statistical analysis of Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen: primary endpoint results, effect estimate…
- BOOST™Independent statistical analysis of Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- BOREASAn independent statistical analysis of the phase 3 BOREAS trial of dupilumab versus placebo in COPD with type 2 inflammation, covering the negative binomial exacerbation analysis, MMRM lung-function and symptom endpoints, logistic…
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BOSTONIndependent statistical analysis of the phase 3 BOSTON trial of selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in multiple myeloma, including PFS, response, overall survival, safety, and statistical methodology.
- BR.21An independent statistical analysis of BR.21, the randomized phase 3 trial of OSI-774 (Tarceva, erlotinib HCl) in patients with stage III or stage IV non-small cell lung cancer.
- BRAVE-EPAIndependent statistical analysis of Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02719327).
- BRAVOComplete statistical analysis of the BRAVO phase 3 trial of laquinimod in participants with relapsing-remitting multiple sclerosis, including its annualized confirmed relapse-rate analysis, negative binomial regression methodology, confidence intervals, and statistical interpretation.
- BRAVOIndependent statistical analysis of A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO): primary endpoint results, effect estimate with…
- BREAKWATERIndependent statistical analysis of the BREAKWATER phase 3 trial of encorafenib plus cetuximab with or without chemotherapy in previously untreated metastatic colorectal cancer, including trial design, primary endpoints, hazard ratios, odds ratios,…
- BREEZE-AD1Independent statistical analysis of A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment: Complete Statistical AnalysisIndependent statistical analysis of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD): Complete Statistical AnalysisIndependent statistical analysis of Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD): primary endpoint results, effect estimate with confidence interval, sample-size planning…